Author response for "Sodium glucose cotransporter (SGLT)-2 inhibitors: do we need them for glucose-lowering, for cardiorenal protection or both?"
Rosalie A. Scholtes, Daniël H. van Raalte(Amsterdam University Medical Centers), Michaël J.B. van Baar(Amsterdam University Medical Centers), Max Nieuwdorp(Amsterdam Institute for Addiction Research), Yuliya Lytvyn(University Health Network), Petter Bjornstad(University of Colorado Denver), David Z.I. Cherney(University Health Network)
Cited by 0
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography
|Nature Medicine|2018|750
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470